News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mallinckrodt Pharmaceuticals (MNK) Releases Human Abuse Liability (HAL) Data For Investigational MNK-155, An Extended-Release Hydrocodone/Acetaminophen Combination


9/3/2014 10:24:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAS VEGAS--(BUSINESS WIRE)--Mallinckrodt (NYSE: MNK) today reported data from a Human Abuse Liability (HAL) study in which both intact and crushed MNK-155 showed lower subjective abuse-related effects than an immediate-release hydrocodone bitartrate/acetaminophen formulation (a generic form of VicodinĀ®). The data will be presented at PAINWeek 2014, a national conference on pain for frontline practitioners, in Las Vegas, Nevada September 2-6, 2014.

In the HAL study, intact and crushed MNK-155 demonstrated statistically significant (p <0.001) lower measures of drug liking, drug high and good drug effects compared with comparable doses of intact immediate-release hydrocodone bitartrate/acetaminophen when measured at the peak drug effect (Emax). It also took significantly longer for intact and crushed MNK-155 to reach peak drug effect compared with intact immediate-release hydrocodone bitartrate/acetaminophen for each of these three measures (p =0.029).

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES